Q1 2025 BioCryst Pharmaceuticals Inc Earnings Call Transcript
Key Points
- BioCryst Pharmaceuticals Inc (BCRX) reported a strong first quarter with revenue of $145.5 million, driven by ORLADEYO sales.
- The company raised its annual revenue guidance for ORLADEYO to between $580 million and $600 million, indicating 33% to 37% growth over the previous year.
- BioCryst Pharmaceuticals Inc (BCRX) achieved a significant improvement in the paid rate for ORLADEYO, reaching 84%, which was expected to take three years but was accomplished in four months.
- The company is on track to be profitable on a full-year basis in 2025, a year earlier than previously planned.
- BioCryst Pharmaceuticals Inc (BCRX) paid down $75 million of its debt, reducing outstanding debt to $249 million and saving approximately $23 million in interest payments over the life of the debt.
- The typical revenue jump in Q2 will be less pronounced than in prior years due to the accelerated revenue capture in Q1.
- Operating expenses increased to $102.9 million, up from $93.6 million in the same quarter last year, driven by commercial expansion and support activities.
- The company faces challenges in conducting clinical trials for rare diseases like Netherton syndrome due to the lack of existing therapies and organized patient advocacy.
- The path to achieving $1 billion in global revenue by 2029 for ORLADEYO is still dependent on capturing more patients and maintaining growth momentum.
- The pediatric launch of ORLADEYO, while promising, has not yet been quantified in terms of revenue impact, and the uptake dynamics remain uncertain.
Good day and welcome to the BioCryst first quarter 2025 earnings conference call. (Operator Instructions) Please note that this event is being recorded.
I would now like to turn the conference over to John Bluth with investor relations with BioCryst. Please go ahead.
Thank you. Good morning and welcome to BioCryst's first quarter 2025 corporate update and financial results conference call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; Chief Commercial Officer, Charlie Gayer; and Chief R&D Officer, Dr. Helen Thackray. Following our remarks, we'll answer your questions.
Today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
